Effectiveness of biosimilar drugs in the treatment of renal anemia: A case series
Introduction Patients with chronic kidney disease usually have anemia secondary to an erythropoietin deficit. The emergence of biosimilar drugs of erythropoiesis-stimulating agents ensures broader access to these treatments. Objective This study analyzes the effectiveness of an epoetin α biosim...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN ES |
| Publicado: |
Medwave Estudios Limitada
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a2ce73468f3043b2a5060f8e35081468 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:a2ce73468f3043b2a5060f8e35081468 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:a2ce73468f3043b2a5060f8e350814682021-11-26T15:43:55ZEffectiveness of biosimilar drugs in the treatment of renal anemia: A case series10.5867/medwave.2021.09.84740717-6384https://doaj.org/article/a2ce73468f3043b2a5060f8e350814682021-10-01T00:00:00Zhttps://www.medwave.cl/link.cgi/Medwave/Estudios/Investigacion/8474.acthttps://doaj.org/toc/0717-6384Introduction Patients with chronic kidney disease usually have anemia secondary to an erythropoietin deficit. The emergence of biosimilar drugs of erythropoiesis-stimulating agents ensures broader access to these treatments. Objective This study analyzes the effectiveness of an epoetin α biosimilar drug in chronic kidney disease patients with anemia. Methods This observational retrospective study enrolled 111 consecutive outpatients with chronic kidney disease and anemia and criteria for using erythropoiesis-stimulating agents. We collected baseline epidemiological and comorbidity data, as well as hematological and renal function infor-mation. We analyzed the effectiveness of the biosimilar agent in naïve patients and those who already had other erythropoiesis-stimulating agents. Results The 111 included patients had a mean age of 83 ± 8 years, and 54% were males. We found that patients who previously received erythropoiesis-stimulating agents, maintained hemoglobin values at two months of treatment with the biosimilar, while the naïve group significantly raised their hemoglobin values (P < 0.001). Renal function remained stable within the whole sample. The cost of using erythropoiesis-stimulating agents was reduced by a mean of 82 ± 17% with the biosimilar drug. Conclusion Using a biosimilar of epoetin α is effective in patients with chronic kidney disease and anemia and significantly reduces costs.Patricia Muñoz RamosYohana Gil GiraldoVicente Álvarez ChivaMedwave Estudios Limitadaarticleanemiabiosimilarchronic kidney diseaseerythropoietin stimulating agentsMedicineRMedicine (General)R5-920ENESMedwave, Vol 21, Iss 09, Pp e8474-e8474 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN ES |
| topic |
anemia biosimilar chronic kidney disease erythropoietin stimulating agents Medicine R Medicine (General) R5-920 |
| spellingShingle |
anemia biosimilar chronic kidney disease erythropoietin stimulating agents Medicine R Medicine (General) R5-920 Patricia Muñoz Ramos Yohana Gil Giraldo Vicente Álvarez Chiva Effectiveness of biosimilar drugs in the treatment of renal anemia: A case series |
| description |
Introduction
Patients with chronic kidney disease usually have anemia secondary to an erythropoietin deficit. The emergence of biosimilar drugs of erythropoiesis-stimulating agents ensures broader access to these treatments.
Objective
This study analyzes the effectiveness of an epoetin α biosimilar drug in chronic kidney disease patients with anemia.
Methods
This observational retrospective study enrolled 111 consecutive outpatients with chronic kidney disease and anemia and criteria for using erythropoiesis-stimulating agents. We collected baseline epidemiological and comorbidity data, as well as hematological and renal function infor-mation. We analyzed the effectiveness of the biosimilar agent in naïve patients and those who already had other erythropoiesis-stimulating agents.
Results
The 111 included patients had a mean age of 83 ± 8 years, and 54% were males. We found that patients who previously received erythropoiesis-stimulating agents, maintained hemoglobin values at two months of treatment with the biosimilar, while the naïve group significantly raised their hemoglobin values (P < 0.001). Renal function remained stable within the whole sample. The cost of using erythropoiesis-stimulating agents was reduced by a mean of 82 ± 17% with the biosimilar drug.
Conclusion
Using a biosimilar of epoetin α is effective in patients with chronic kidney disease and anemia and significantly reduces costs. |
| format |
article |
| author |
Patricia Muñoz Ramos Yohana Gil Giraldo Vicente Álvarez Chiva |
| author_facet |
Patricia Muñoz Ramos Yohana Gil Giraldo Vicente Álvarez Chiva |
| author_sort |
Patricia Muñoz Ramos |
| title |
Effectiveness of biosimilar drugs in the treatment of renal anemia: A case series |
| title_short |
Effectiveness of biosimilar drugs in the treatment of renal anemia: A case series |
| title_full |
Effectiveness of biosimilar drugs in the treatment of renal anemia: A case series |
| title_fullStr |
Effectiveness of biosimilar drugs in the treatment of renal anemia: A case series |
| title_full_unstemmed |
Effectiveness of biosimilar drugs in the treatment of renal anemia: A case series |
| title_sort |
effectiveness of biosimilar drugs in the treatment of renal anemia: a case series |
| publisher |
Medwave Estudios Limitada |
| publishDate |
2021 |
| url |
https://doaj.org/article/a2ce73468f3043b2a5060f8e35081468 |
| work_keys_str_mv |
AT patriciamunozramos effectivenessofbiosimilardrugsinthetreatmentofrenalanemiaacaseseries AT yohanagilgiraldo effectivenessofbiosimilardrugsinthetreatmentofrenalanemiaacaseseries AT vicentealvarezchiva effectivenessofbiosimilardrugsinthetreatmentofrenalanemiaacaseseries |
| _version_ |
1718409309191143424 |